New Risk • May 23
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -฿116m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-฿116m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 39x increase in shares outstanding). Minor Risks Revenue is less than US$5m (฿159m revenue, or US$4.9m). Market cap is less than US$100m (฿1.09b market cap, or US$33.5m). Reported Earnings • May 23
First quarter 2026 earnings released: ฿0.014 loss per share (vs ฿0.18 loss in 1Q 2025) First quarter 2026 results: ฿0.014 loss per share. Revenue: ฿83.0m (up 56% from 1Q 2025). Net loss: ฿335.9m (loss widened ฿283.2m from 1Q 2025). Ankündigung • Mar 19
X Bioscience Public Company Limited, Annual General Meeting, Apr 30, 2026 X Bioscience Public Company Limited, Annual General Meeting, Apr 30, 2026, at 13:00 SE Asia Standard Time. New Risk • Mar 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -฿79m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-฿79m free cash flow). Share price has been highly volatile over the past 3 months (36% average weekly change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (254% increase in shares outstanding). Market cap is less than US$10m (฿63.0m market cap, or US$2.03m). Minor Risk Revenue is less than US$5m (฿130m revenue, or US$4.2m). Reported Earnings • Mar 01
Full year 2025 earnings released: ฿1.13 loss per share (vs ฿1.41 loss in FY 2024) Full year 2025 results: ฿1.13 loss per share. Revenue: ฿129.7m (down 59% from FY 2024). Net loss: ฿451.9m (loss widened 74% from FY 2024). Ankündigung • Feb 27
X Bioscience Public Company Limited Announces Resignation of Tom Chalernkarnchana as Independent Director, Effective 25 February 2026 X Bioscience Public Company Limited acknowledged the resignation of Mr. Tom Chalernkarnchana from his positions as Independent Director, Audit Committee Member, and Nomination and Remuneration Committee Member of the Company, effective from 25 February 2026 onwards. Ankündigung • Feb 13
X Bioscience Public Company Limited Announces Board Changes At the Board of Directors' Meeting No. 2/2026 of X Bioscience Public Company Limited held on February 11, 2026 at 11:40 hrs. via electronic media in accordance with the Royal Decree on Electronic Meetings B.E. 2563 (2020) and other relevant laws, the meeting passed significant resolutions which are required to be reported to the Stock Exchange of Thailand, as follows: approved the appointment of Miss Thansuda Rungruang as a Director of the Company in replacement of Asst. Prof.Dr.Pattanant Petchchedchoo, who resigned. Ms. Thansuda Rungruang shall hold office for the remaining term of the resigned director (expiring at the 2027 Annual General Meeting of Shareholders). The appointment shall be effective from 11 February 2026 onward. Following the appointment the structure of the Board of Directors shall consists of the following list including the names and positions of individuals who will serve as Directors and/or Independent Directors of the Company:
Mr. Supoj Pannoi: Position: Chairman of the Board of Directors /Independent Director /Audit Committee. Miss Saowanee Khaoubol: Position: Vice Chairman of the Board of Directors /Director /Chief Executive Officer (Acting). Miss Naphat Tavisaengsiri: Position: Director. Mr. Amnart Lertpresertwong: Position: Director. Miss Thansuda Rungruang: Position: Director. Mr. Tom Chalermkarnchana: Position: Independent Director /Audit Committee /Nomination and Remuneration Committee. Mr. Yuthaveera Achawangkul: Position: Independent Director /Nomination and Remuneration Committee. Mr. Sarayut Rueangsuwan: Position: Independent Director /Chairman of the Audit Committee /Chairman of the Nomination and Remuneration Committee. Ankündigung • Jan 08
X Bioscience Public Company Limited Appoints Directors, Effective December 22, 2025 X Bioscience Public Company Limited at the board of directors meeting held on December 22, 2025 in accordance with the Emergency Decree on Electronic Meetings B.E. 2563 (2020) and other applicable laws, the company hereby reports the following material resolutions to The Stock Exchange of Thailand as follows: Resolved to approve the appointment of 3 directors to replace the resigning directors as follows: Asst. Prof. Dr. Pattanant Petchchedchoo was appointed as Independent Director and Chairman of the Board of Directors, replacing Mr. Tanawat Ueasiripan, with a term of office equal to the remaining term of the resigning director (to expire at the Annual General Meeting of Shareholders for the year 2027). The appointment shall be effective from 22 December 2025 onwards. Mr. Supoj Pannoi was appointed as Independent Director and Member of the Audit Committee, replacing Mr. Sivaporn Chomsuwan, with a term of office equal to the remaining term of the resigning director (to expire at the Annual General Meeting of Shareholders for the year 2027). The appointment shall be effective from 22 December 2025 onwards. Mr. Amnart Lertpresertwong was appointed as Director, replacing Mr. Phurit Wongkham, with a term of office equal to the remaining term of the resigning director (to expire at the Annual General Meeting of Shareholders for the year 2026). The appointment shall be effective from 22 December 2025 onwards. Following the appointment of the above directors, the structure of the Company's Board of Directors shall comprise the following persons as Directors and/or Independent Directors of the Company: Asst. Prof. Dr. Pattanant Petchchedchoo, Independent Director /Chairman of the Board of Directors; Miss Saowanee Khaoubol, Director /Acting Chief Executive Officer; Miss Naphat Tavisaengsiri, Director; Mr. Amnart Lertpresertwong, Director; Mr. Yuthaveera Achawangkul, Independent Director /Nomination and Remuneration Committee; Mr. Sarayut Rueangsuwan, Independent Director /Chairman of the Audit Committee /Chairman of the Nomination and Remuneration Committee; Mr. Supoj Pannoi, Independent Director /Audit Committee; Mr.Tom Chalermkarnchana, Independent Director /Audit Committee /Nomination and Remuneration Committee. New Risk • Dec 30
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 278% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (38% average weekly change). Earnings have declined by 5.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (278% increase in shares outstanding). Market cap is less than US$10m (฿178.6m market cap, or US$5.68m). Ankündigung • Dec 24
X Bioscience Public Company Limited has filed a Follow-on Equity Offering in the amount of THB 609.186795 million. X Bioscience Public Company Limited has filed a Follow-on Equity Offering in the amount of THB 609.186795 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 15,229,669,870
Price\Range: THB 0.04
Transaction Features: Rights Offering Reported Earnings • Nov 16
Third quarter 2025 earnings released: ฿0.058 loss per share (vs ฿0.21 loss in 3Q 2024) Third quarter 2025 results: ฿0.058 loss per share. Revenue: ฿25.8m (down 65% from 3Q 2024). Net loss: ฿117.5m (loss widened 254% from 3Q 2024). Ankündigung • Aug 21
X Bioscience Public Company Limited has filed a Follow-on Equity Offering in the amount of THB 611.386497 million. X Bioscience Public Company Limited has filed a Follow-on Equity Offering in the amount of THB 611.386497 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,596,391,156
Price\Range: THB 0.17
Transaction Features: Rights Offering New Risk • Aug 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -฿57m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-฿57m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Minor Risk Market cap is less than US$100m (฿356.6m market cap, or US$11.0m). Reported Earnings • Aug 15
Second quarter 2025 earnings released: ฿36.84 loss per share (vs ฿0.043 loss in 2Q 2024) Second quarter 2025 results: ฿36.84 loss per share (further deteriorated from ฿0.043 loss in 2Q 2024). Revenue: ฿26.7m (down 63% from 2Q 2024). Net loss: ฿74.4m (loss widened 65% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings. Ankündigung • Jun 06
X Bioscience Public Company Limited announced that it expects to receive THB 1.3 billion in funding X Bioscience Public Company Limited announced a private placement to issue 13,000,000,000 ordinary share at an issue price of TBH 0.0 for the proceeds of TBH 1,300,000,000 on June 5, 2025. The transaction involves participation of 13 individual investors including Mr. Tassapon Bijleveld for 4,950,000,000 shares, Miss Nichanant Suwatsakulsawasd for 1,500,000,000, Mr. Nivat Napakornwattananon for 1,500,000,000 and others The transaction is approved by board of directors.. New Risk • May 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -฿79m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-฿79m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 10.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (104% increase in shares outstanding). Market cap is less than US$10m (฿230.8m market cap, or US$6.91m). Reported Earnings • May 17
First quarter 2025 earnings released: ฿0.031 loss per share (vs ฿0.046 loss in 1Q 2024) First quarter 2025 results: ฿0.031 loss per share. Revenue: ฿62.4m (down 18% from 1Q 2024). Net loss: ฿62.5m (loss widened 33% from 1Q 2024). Ankündigung • Mar 27
X Bioscience Public Company Limited has completed a Follow-on Equity Offering in the amount of THB 3 million. X Bioscience Public Company Limited has completed a Follow-on Equity Offering in the amount of THB 3 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 18,750,000
Price\Range: THB 0.16
Transaction Features: Subsequent Direct Listing Ankündigung • Mar 20
X Bioscience Public Company Limited Announces Resignation of Satita Balasuvatthi as Director X Bioscience Public Company Limited announced resignation of Miss Satita Balasuvatthi as director, Expire Date is 19 March 2025, Terminate Reason: Resigned from position /the company due to Attending to Private Matters. New Risk • Mar 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ฿332.7m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (102% increase in shares outstanding). Market cap is less than US$10m (฿332.7m market cap, or US$9.90m). Ankündigung • Mar 18
X Bioscience Public Company Limited, Annual General Meeting, Apr 29, 2025 X Bioscience Public Company Limited, Annual General Meeting, Apr 29, 2025, at 10:00 SE Asia Standard Time. Reported Earnings • Mar 04
Full year 2024 earnings released: ฿0.20 loss per share (vs ฿0.17 loss in FY 2023) Full year 2024 results: ฿0.20 loss per share (further deteriorated from ฿0.17 loss in FY 2023). Revenue: ฿319.2m (up 2.4% from FY 2023). Net loss: ฿260.2m (loss widened 76% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 61% per year, which means it is performing significantly worse than earnings. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (฿539.3m market cap, or US$15.6m). New Risk • Jan 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Thai stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 20% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (฿606.7m market cap, or US$17.5m). New Risk • Nov 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -฿107m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-฿107m free cash flow). Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (฿943.8m market cap, or US$27.0m). Reported Earnings • Aug 15
Second quarter 2024 earnings released: ฿0.043 loss per share (vs ฿0.033 loss in 2Q 2023) Second quarter 2024 results: ฿0.043 loss per share (further deteriorated from ฿0.033 loss in 2Q 2023). Revenue: ฿71.8m (down 7.7% from 2Q 2023). Net loss: ฿45.2m (loss widened 65% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. New Risk • Jul 14
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (฿885.2m market cap, or US$24.5m). Reported Earnings • May 15
First quarter 2024 earnings released First quarter 2024 results: Revenue: ฿75.8m (down 6.0% from 1Q 2023). Net loss: ฿47.1m (loss widened 64% from 1Q 2023). Ankündigung • Mar 30
Wow Factor Public Company Limited Announces Chief Financial Officer Changes, Effective April 1, 2024 Wow Factor Public Company Limited announced resignation of Phornpravee Chansuwan as Chief Financial Officer. Effective Date of Termination 01 April, 2024. The company announced appointment of Wilawan Lowudomsap as Chief Financial Officer (Acting). Effective Date of Appointment 01 April, 2024. Ankündigung • Feb 16
Wow Factor Public Company Limited, Annual General Meeting, Apr 30, 2024 Wow Factor Public Company Limited, Annual General Meeting, Apr 30, 2024, at 10:00 SE Asia Standard Time. Agenda: To consider and certify the minutes of the Extraordinary General Meeting of shareholders No.2/2023 which was held on November 21, 2023; to acknowledger the performance of business operation of the Company for fiscal year ended December 31, 2023; to consider and approve the statement of financial position and the profit and loss statement for fiscal year ended December 31, 2023; to consider and approve the appropriate of profit as legal reserve as prescribed by the laws and the omission of dividend from the Company's business operation performance for the year 2023; to consider and approve the appointment of director replacing those retiring by rotation; to consider and approve the Board of Directors' and the Sub-Committees' remuneration for the year of 2024; to consider and approve the appointment of auditors of the Company and its subsidiaries and determination of audit fee for the year of 2024; and to consider other issues. New Risk • Feb 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Thai stocks, typically moving 10.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10.0% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (฿948.1m market cap, or US$26.3m). Ankündigung • Nov 22
Wow Factor Public Company Limited Announces Resignation of Issaraporn Thanupon as Independent Director / Audit Committee / Chairman of the Nomination and Remuneration Committee Wow Factor Public Company Limited announced that Mrs. Issaraporn Thanupon informed resignation from the position of Independent Director /Audit Committee /Chairman of the Nomination and Remuneration Committee because her personal duties. The resignation has been effected from November 20, 2023 onwards. Ankündigung • Nov 15
Wow Factor Public Company Limited Announces Resignation of Member of the Audit Committee and the Appointment of the New Director to Replace the Resigned Director Wow Factor Public Company Limited at its board meeting held on November 13, 2023 announced resignation from the position of Independent Director /Audit Committee /Nomination and Remuneration Committee of Mr. Chanchai Kanlueang, effective from November 14, 2023 onwards, appoint Mr. Tom Chalermkarnchana as the position of Independent Director /Audit Committee /Nomination and Remuneration Committee to replace Mr. Chanchai Kanlueang, effective from November 14, 2023 onwards. As a result of the appointment of a new director, the structure of the Board of Directors of the Company will consist of the following committee serving as directors and/or independent directors of the Company. Mr. Tanawat Ueasiripan Vice Chairman of the Board of Directors /Director; Miss Saowanee Khaoubol Director /Chief Executive Officer (Acting); Miss Naphat Tavisaengsiri Director; Mr. Yuthaveera Achawangkul Director; Mr. Phurit Wongkham Director. Mr. Somboon Prasobpiboon Independent Director Mr. Chanatip Pumhiran: Independent Director /Chairman of the Audit Committee /Nomination and Remuneration Committee; Mrs. Issaraporn Thanupon Independent Director /Audit Committee /Chairman of the Nomination and Remuneration Committee; Mr. Tom Chalermkarnchana Independent Director /Audit Committee /Nomination and Remuneration Committee. Reported Earnings • Nov 14
Third quarter 2023 earnings released: ฿0.03 loss per share (vs ฿0.12 loss in 3Q 2022) Third quarter 2023 results: ฿0.03 loss per share (improved from ฿0.12 loss in 3Q 2022). Revenue: ฿76.7m (down 54% from 3Q 2022). Net loss: ฿26.5m (loss narrowed 73% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. New Risk • Sep 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (฿866.9m market cap, or US$24.4m). Ankündigung • Sep 07
Wow Factor Public Company Limited announced that it has received THB 456.1 million in funding On September 5, 2023, Wow Factor Public Company Limited closed the transaction, The company will now issue 430,000,000 shares at an issue price of THB 1 per share for the gross proceeds of THB 430,000,000. Ankündigung • Aug 26
Wow Factor Public Company Limited Announces Board Changes, Effective from August 25, 2023 Wow Factor Public Company Limited at its board meeting held on August 25, 2023 approved to Appoint Miss Naphat Tavisaengsiri as a director to replace Mr. Supreedee Nimitkul, effective from August 25, 2023 onwards, with the same term of office as the remaining term of the resigned director (The term expires at the 2024 Annual General Meeting of Shareholders) As a result of the appointment of a new director, structure of the Board of Directors for the Company will consist of the following persons serving as directors and/or independent directors of the Company. Mr. Tanawat Ueasiripan as Director /Vice Chairman of the Board of Directors; Miss Saowanee Khaoubol as Director /Acting Chief Executive Office; Dr. Phornpravee Chansuwan as Director; Dr. Somboon Prasobpiboon as Independent Director; Miss Chanpen Siripatumanant as Independent Director; Mr. Chanatip Pumhiran as Independent Director /Chairman of the Audit Committee /Member of the Nomination and Remuneration Committee; Dr. Issaraporn Thanupon as Independent Director /Member of the Audit Committee /Chairman of the Nomination and Remuneration Committee; Mr. Chanchai Kanluang as Independent Director /Member of the Audit Committee /Member of the Nomination and Remuneration Committee; Miss Naphat Tavisaengsiri as Director. Reported Earnings • Aug 13
Second quarter 2023 earnings released: ฿0.033 loss per share (vs ฿0.14 loss in 2Q 2022) Second quarter 2023 results: ฿0.033 loss per share (improved from ฿0.14 loss in 2Q 2022). Revenue: ฿77.8m (down 55% from 2Q 2022). Net loss: ฿27.3m (loss narrowed 76% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings. Ankündigung • May 04
Wow Factor Public Company Limited Announces Resignation of Supreedee Nimitkul as Independent Director Wow Factor Public Company Limited announced that Mr. Supreedee Nimitkul has submitted letters to the Company declaring his intention to resign from the positions of Independent Director, effective from 1 May 2023 onwards. The Company will conduct its recruitment process to select and appoint a qualified person to fill the vacant Independent Director position. Ankündigung • Jan 20
Wow Factor Public Company Limited Announces Board Changes Wow Factor Public Company Limited announced that Board of Directors' Meeting held on 19 January 2023. The Meeting considered and resolved the significant resolution which can be summarized as follows: To Appoint Mr. Somboon Prasobpiboon as a director of the Company to replace Miss Vimol Hanpanishkitkarn effective from 19 January 2023 onwards, with the same term of office as the remaining term of the resigned director (term expired in 2025); To Appoint Mr. Chanchai Kanluang as a Member of the Audit Committee /Member of the Nomination and Remuneration Committee to replace Miss Yaowarote Klinboon, effective from 19 January 2023 onwards. To Appoint Dr. Issaraporn Thanupon as a Chairman of Nomination and Remuneration Committee, effective from 19 January 2023 onwards. As a result of the appointment of 1 new director, the structure of the Board of Directors of the Company will consist of the following persons serving as directors and/or independent directors of the Company. Mr. Tanawat Ueasiripan: Director /Vice Chairman of the Board of Directors; Miss Saowanee Khaoubol: Director /Acting Chief Executive Office; Dr. Phornpravee Chansuwan: Director; Mr. Somboon Prasobpiboon: Independent Director; Mr. Supreedee Nimitkul: Independent Director; Mr. Chanatip Pumhiran: Independent Director /Chairman of the Audit Committee /Member of the Nomination and Remuneration Committee; Dr. Issaraporn Thanupon: Independent Director /Member of the Audit Committee /Chairman of the Nomination and Remuneration Committee; Mr. Chanchai Kanluang: Independent Director /Member of the Audit Committee /Member of the Nomination and Remuneration Committee. Board Change • Jan 01
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. CFO & Director Vimol Hanpanishkitkarn is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Dec 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Chanatip Pumhiran was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 16
Third quarter 2022 earnings released: ฿0.12 loss per share (vs ฿0.089 loss in 3Q 2021) Third quarter 2022 results: ฿0.12 loss per share (further deteriorated from ฿0.089 loss in 3Q 2021). Revenue: ฿166.7m (up 95% from 3Q 2021). Net loss: ฿99.9m (loss widened 37% from 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 117 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 13
Second quarter 2022 earnings released: ฿0.14 loss per share (vs ฿0.091 loss in 2Q 2021) Second quarter 2022 results: ฿0.14 loss per share (down from ฿0.091 loss in 2Q 2021). Revenue: ฿171.5m (up 95% from 2Q 2021). Net loss: ฿113.3m (loss widened 53% from 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance. Board Change • Jun 02
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Director Sarinya Mahadumrongkul was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 16
First quarter 2022 earnings released: ฿0.11 loss per share (vs ฿0.075 loss in 1Q 2021) First quarter 2022 results: ฿0.11 loss per share (down from ฿0.075 loss in 1Q 2021). Revenue: ฿153.5m (up 60% from 1Q 2021). Net loss: ฿89.5m (loss widened 47% from 1Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 123 percentage points per year, which is a significant difference in performance. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jenvit Jivakulchainan was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 18
Third quarter 2021 earnings released: ฿0.089 loss per share (vs ฿0.021 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ฿85.5m (down 21% from 3Q 2020). Net loss: ฿72.7m (loss widened 330% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 85% per year, which means it is well ahead of earnings. Reported Earnings • Aug 18
Second quarter 2021 earnings released: ฿0.091 loss per share (vs ฿0.045 loss in 2Q 2020) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: ฿87.8m (down 28% from 2Q 2020). Net loss: ฿74.0m (loss widened 194% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 75% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 19
First quarter 2021 earnings released: ฿0.005 loss per share (vs ฿0.045 loss in 1Q 2020) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: ฿96.0m (down 5.7% from 1Q 2020). Net loss: ฿60.9m (loss widened 91% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 54% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 02
Full year 2020 earnings released: ฿0.023 loss per share (vs ฿0.002 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: ฿415.6m (down 2.1% from FY 2019). Net loss: ฿238.8m (loss widened ฿216.9m from FY 2019). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 57% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 24
New 90-day low: ฿0.21 The company is down 9.0% from its price of ฿0.23 on 26 November 2020. The Thai market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 26% over the same period. Is New 90 Day High Low • Jan 19
New 90-day high: ฿0.30 The company is up 43% from its price of ฿0.21 on 21 October 2020. The Thai market is up 25% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 32% over the same period. Is New 90 Day High Low • Dec 04
New 90-day high: ฿0.27 The company is up 69% from its price of ฿0.16 on 03 September 2020. The Thai market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 16% over the same period. Is New 90 Day High Low • Nov 17
New 90-day high: ฿0.26 The company is up 44% from its price of ฿0.18 on 19 August 2020. The Thai market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 7.0% over the same period. Reported Earnings • Nov 15
Third quarter 2020 earnings released: ฿0.001 loss per share The company reported a soft third quarter result with weaker earnings and control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: ฿108.8m (up 8.2% from 3Q 2019). Net loss: ฿16.9m (down 110% from profit in 3Q 2019). Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Sep 28
New 90-day high: ฿0.25 The company is up 92% from its price of ฿0.13 on 30 June 2020. The Thai market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 13% over the same period. Is New 90 Day High Low • Sep 18
New 90-day high: ฿0.23 The company is up 77% from its price of ฿0.13 on 19 June 2020. The Thai market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 20% over the same period. 
